KR840007356A - Pharmaceutical Compositions Containing Napazathrom - Google Patents

Pharmaceutical Compositions Containing Napazathrom Download PDF

Info

Publication number
KR840007356A
KR840007356A KR1019840000394A KR840000394A KR840007356A KR 840007356 A KR840007356 A KR 840007356A KR 1019840000394 A KR1019840000394 A KR 1019840000394A KR 840000394 A KR840000394 A KR 840000394A KR 840007356 A KR840007356 A KR 840007356A
Authority
KR
South Korea
Prior art keywords
napazatrum
ischemia
naphthyloxy
edema
hypertension
Prior art date
Application number
KR1019840000394A
Other languages
Korean (ko)
Inventor
마르딘(외 7) 미다트
Original Assignee
게르하르트 뷔네만, 에리히 데 브릿쯔
바이엘 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게르하르트 뷔네만, 에리히 데 브릿쯔, 바이엘 아크티엔 게젤샤프트 filed Critical 게르하르트 뷔네만, 에리히 데 브릿쯔
Publication of KR840007356A publication Critical patent/KR840007356A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

내용 없음.No content.

Description

나파자트롬을 함유한 약제조성물Pharmaceutical Compositions Containing Napazathrom

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (4)

허혈증, 심장리듬장애, 눈 및 피부의 염증, 류마티즘, 알레르기성 및 천식성 질병, ARDS, 폐전색증, 부종, 고혈압, 산소중독 및 궤양의 치료 및 예방을 위한 나파자트름의 용도.Use of napazatrum for the treatment and prevention of ischemia, heart rhythm disorders, eye and skin inflammation, rheumatism, allergic and asthmatic diseases, ARDS, pulmonary embolism, edema, hypertension, oxygen poisoning and ulcers. 제1항에 있어서, 심근허혈증으로 인한 심장경색을 치료하기 위한 나파자트름의 용도.The use of napazatrum according to claim 1 for the treatment of heart infarction due to myocardial ischemia. 임의로 불활성 유기용매 및/또는 물 존재하 및 염기성 또는 산성촉매존재하에, 약 10내지 200℃의 온도에서, 2-(2-나프틸옥시)-에틸히드라진을 아세토아세트산 유도체와 반응시키거나, 3-메틸피라졸린-5-온을 2-(2-나프틸옥시)-에틸 유도체와 반응시키거나, 2-(2-나프틸옥시(-에틸히드라진을 테트롤산 유도체와 반응시켜 나파자트름을 제조한 후, 이 나파자트름 치료학적 유효량을 약리학적으로 허용되는 희석제 또는 부형제와 혼합한 다음, 적절한 투여형태로 제조함을 특징으로 하여 류머티즘 치료제, 항 알레르기체, 천식치료제, 기관지확장치료제, 고혈압치료제, 부종치료제, 부정맥치료제, 허혈증치료제 및/또는 위보호제를 제조하는 방법.Reacting 2- (2-naphthyloxy) -ethylhydrazine with an acetoacetic acid derivative, optionally in the presence of an inert organic solvent and / or water and in the presence of a basic or acidic catalyst, or 3- Methylpyrazoline-5-one is reacted with a 2- (2-naphthyloxy) -ethyl derivative or 2- (2-naphthyloxy (-ethylhydrazine is reacted with a tetrolic acid derivative to prepare napazatrum The therapeutically effective amount of napazatrum is then mixed with a pharmacologically acceptable diluent or excipient, and then prepared in an appropriate dosage form, thereby treating rheumatism, antiallergic agents, asthma, bronchial accumulators, and hypertension. Edema, arrhythmia, ischemia and / or gastric protective agent. 허혈증, 심장리듬장애, 눈 및/또는 피부의 염증, 류마티즘, 알레르기성 및/또는 천식성 질병, ARDS, 폐전색증, 부종, 고혈압, 산소중독 및 궤양의 예방 및 치료시 사용 용도에 대한 설명서가 첨부된, 약리학적 유효 성분으로서 나파자트롬을 함유하는 시판용 포장단위(package).Attached instructions for use in the prevention and treatment of ischemia, heart rhythm disorders, inflammation of the eyes and / or skin, rheumatism, allergic and / or asthmatic diseases, ARDS, pulmonary embolism, edema, hypertension, oxygen poisoning and ulcers Commercially available packaging containing napazathrom as a pharmacologically active ingredient. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019840000394A 1983-01-28 1984-01-28 Pharmaceutical Compositions Containing Napazathrom KR840007356A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833302811 DE3302811A1 (en) 1983-01-28 1983-01-28 Use of nafazatrom in the therapy of cardiac dysrhythmias and myocardial ischaemias, pharmaceutical compositions for this purpose and process for the preparation thereof
DEP3302811.7 1983-01-28

Publications (1)

Publication Number Publication Date
KR840007356A true KR840007356A (en) 1984-12-07

Family

ID=6189416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840000394A KR840007356A (en) 1983-01-28 1984-01-28 Pharmaceutical Compositions Containing Napazathrom

Country Status (5)

Country Link
JP (1) JPS59141517A (en)
KR (1) KR840007356A (en)
DE (1) DE3302811A1 (en)
IE (1) IE840198L (en)
ZA (1) ZA84637B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment
JPWO2005012255A1 (en) * 2003-08-01 2006-09-14 三菱ウェルファーマ株式会社 Treatment for inflammatory joint diseases

Also Published As

Publication number Publication date
DE3302811A1 (en) 1984-08-02
JPS59141517A (en) 1984-08-14
ZA84637B (en) 1984-09-26
IE840198L (en) 1984-07-28

Similar Documents

Publication Publication Date Title
DE9320925U1 (en) Terfenadine metabolites and their optically pure isomers for the treatment of allergic disorders
KR880000091A (en) Topical Pharmaceutical Compositions Method of Preparation and Use thereof
JPS611623A (en) Permeation promoting composition and method through skin andmembrane by local drug and general drug
NO156690C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE INHANDER DERIVATIVES.
SE8001599L (en) TRANSDERMAL MEDICATION SYSTEM FOR ISOSORBID DINITRATE
DK0920865T3 (en) Pharmaceutical compositions containing norastemizole
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE3172298D1 (en) Pharmaceutical compositions
JP2001510826A5 (en)
DE69133077D1 (en) Preparation of pharmaceutical compositions containing ST1435 for topical use
KR840007356A (en) Pharmaceutical Compositions Containing Napazathrom
KR960010003A (en) L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same
CN108078999B (en) Pharmaceutical composition for preventing and treating cerebral arterial thrombosis and preparation method and application thereof
HUP0000108A2 (en) Use of angiotensin ii antagonists for the manufacture of medicament suitable for treating symptomatic heart failure
RU2005122466A (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING THE COMBINATION OF CALCITRIOL AND CLOBETHAZOL PROPIONATE
GB977214A (en) Chemical compounds
IE790157L (en) Therapeutic agents
WO2007107663A2 (en) Use of (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide for treating inflammatory skin pathologies
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
MY115229A (en) Substituted chromanylsulfonyl(thio) ureas, processes for their preparation their use in pharmaceutical preparations, and pharmaceutical preparations comprising them.
GB1588095A (en) Composition for the treatment of scabies
KR880005920A (en) Leukocyte interferon composition and skin treatment in the human body
EP0009793A3 (en) Pharmaceutical composition containing a derivative of 2-(retinylidene)-malonic acid, manufacturing process and application
RU2076698C1 (en) Ointment exhibiting antihyperkeratic activity
JPH04198135A (en) External preparation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid